Cargando…
Light at the ENDothelium-role of Sox17 and Runx1 in endothelial dysfunction and pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease that is characterized by an obliterative vasculopathy of the distal pulmonary circulation. Despite significant progress in our understanding of the pathophysiology, currently approved medical therapies for PAH act primarily as pulmonary...
Autores principales: | Simmons Beck, Robert, Liang, Olin D., Klinger, James R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656768/ https://www.ncbi.nlm.nih.gov/pubmed/38028440 http://dx.doi.org/10.3389/fcvm.2023.1274033 |
Ejemplares similares
-
Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertension
por: Jeong, Euy-Myoung, et al.
Publicado: (2022) -
Pulmonary artery endothelium resident endothelial colony-forming cells in pulmonary arterial hypertension
por: Duong, Heng T., et al.
Publicado: (2011) -
SOX17 enhancer variants disrupt transcription factor binding and enhancer inactivity drives pulmonary hypertension
por: Walters, Rachel, et al.
Publicado: (2023) -
An emerging phenotype of pulmonary arterial hypertension patients carrying SOX17 variants
por: Montani, David, et al.
Publicado: (2022) -
Human yolk sac-like haematopoiesis generates RUNX1-, GFI1- and/or GFI1B-dependent blood and SOX17-positive endothelium
por: Bruveris, Freya F., et al.
Publicado: (2020)